INNIO N.V. Ordinary Shares vs Moderna, Inc. — how do they compare? INNIO N.V. Ordinary Shares trades at $16.22 (market cap $13.73B), while Moderna, Inc. trades at $222.68 (market cap $86.33B). The key difference: Moderna, Inc. is far larger — about 6.3× INNIO N.V. Ordinary Shares's market cap, and Moderna, Inc. is trading nearer its 52-week high, INNIO N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold INNIO N.V. Ordinary Shares for 0 Days and Moderna, Inc. for 59 Days on average.
| INIO | MRNA | |
|---|---|---|
Market Cap | $13.73B | $86.33B |
Volume | 5,012,195 | 13,361,426 |
Sector | Industrials | Health |
52-Week High | $41.13 | $226.30 |
52-Week Low | $16.50 | $22.36 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $15.39B | $82.48B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $226.30, up 5.88% with strong technical momentum as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative profitability margins (-142.58% net income margin) and declining revenue from pandemic peaks. Technical indicators show bullish momentum with price above key support levels, while analyst sentiment remains divided with a $115.70 consensus target well below current levels.
The outlook balances Nasdaq inclusion benefits against valuation concerns after a 500% 2026 rally. Investment opportunity lies in the cancer vaccine pipeline growth, while risks include sustained profitability challenges and high valuation multiples (P/S 38.5) that may not justify current price levels given declining revenue trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
INNIO Group designs, manufactures, and services reciprocating gas engines for distributed power generation under its Jenbacher and Waukesha brands, serving applications from data centers to industrial and grid-stabilization uses.
Read more on INIO →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →